Cellectar Biosciences Inc (CLRB)

Sector:
CONSUMER DISCRETIONARY
Industry:
CONSUMER SERVICES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
James V. Caruso
Employees:
10
3301 AGRICULTURE DRIVE, MADISON, WI 53716
(608) 441-8120

Cellectar Biosciences, Inc. focuses on the discovery, development, and commercialization of drugs for cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies.

Data derived from most recent annual or quarterly report
Market Cap 356.831 Million Shares Outstanding61.101 Million Avg 30-day Volume 68.838 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.24
Price to Revenue0.0 Debt to Equity0.0 EBITDA-31.459 Million
Price to Book Value0.1312 Operating Margin0.0 Enterprise Value-21.037 Million
Current Ratio4.51 EPS Growth0.037 Quick Ratio4.425
1 Yr BETA -0.1803 52-week High/Low 6.76 / 0.34 Profit Margin0.0
Operating Cash Flow Growth-14.4104 Altman Z-Score-11.7307 Free Cash Flow to Firm -15.9 Million
Earnings Report2022-11-07
View SEC Filings from CLRB instead.

View recent insider trading info

Funds Holding CLRB (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CLRB

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-08-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-21:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-27:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-07:
    Item 8.01: Other Events
  • 8-K: filed on 2022-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-06:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2022-04-26:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-21:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-15:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-25:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    DRISCOLL FREDERICK W

    • Director
    7,800 2022-06-24 2

    NEIS JOHN

    • Director
    7,800 2022-06-24 1

    SWIRSKY DOUGLAS J

    • Director
    11,700 2022-06-24 2

    LOREN STEFAN

    • Director
    7,800 2022-06-24 1

    CHANAN-KHAN ASHER

    • Director
    7,800 2022-06-24 1

    KOLEAN CHAD J CHIEF FINANCIAL OFFICER

    • Officer
    240 2022-02-24 3

    CARUSO JAMES V PRESIDENT AND CEO

    • Officer
    • Director
    1,419,000 2022-01-25 1

    ELEFANT DOV CHIEF FINANCIAL OFFICER

    • Officer
    422,000 2022-01-25 1

    LONGCOR JARROD CHIEF BUSINESS OFFICER

    • Officer
    475,000 2022-01-25 1

    FRIEND JOHN E. II CHIEF MEDICAL OFFICER

    • Officer
    330,000 2021-03-04 0

    HILL STEPHEN A

    • Director
    0 2020-06-24 0

    GRACHEV IGOR D CHIEF MEDICAL OFFICER

    • Officer
    0 2020-01-06 0

    BERNHARDT CHARLES THOMAS III INTERIM CFO

    • Officer
    0 2019-03-09 0

    POSNER BRIAN M CHIEF FINANCIAL OFFICER

    • Officer
    0 2019-01-17 0

    HAMILL JOHN P. INTERIM CFO

    • Officer
    0 2017-09-05 0

    HERTZBERG RICHARD

    • SIGNIFICANT OWNER
    No longer subject to file 2016-08-09 0

    WEICHERT JAMEY P CHIEF SCIENTIFIC OFFICER

    • Officer
    0 2016-05-12 0

    BERNS PAUL L

    • Director
    234,742 2016-04-20 0

    WISCONSIN ALUMNI RESEARCH FOUNDATION

    • 10% Owner
    469,484 2016-04-14 0

    AWM INVESTMENT COMPANY, INC.

    • 10% Owner
    No longer subject to file 2015-12-30 0

    GENN JOHN PATRICK VP OF BUSINESS DEVELOPMENT

    • Officer
    0 2015-02-26 0

    MARXE AUSTIN W & GREENHOUSE DAVID M

    • 10% Owner
    1,142,368 2015-02-03 0

    SZAKACS CAMERON VP OF CLINICAL DEVELOPMENT

    • Officer
    0 2014-11-24 0

    PEDDER SIMON PRESIDENT AND CEO

    • Officer
    • Director
    290,878 2014-08-20 0

    CORMORANT ASSET MANAGEMENT, LLC

    CHEN BIHUA

    CORMORANT GLOBAL HEALTHCARE GP, LLC

    CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP

    • Director
    • 10% Owner
    530,000 2014-08-15 0

    MCNEIL KATHRYN M SEE REMARKS

    • Officer
    0 2014-08-14 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    SWIRSKY DOUGLAS J - Director

    2022-08-01 18:01:54 -0400 2022-06-24 A 11,700 a 11,700 direct

    NEIS JOHN - Director

    2022-08-01 18:01:38 -0400 2022-06-24 A 7,800 a 7,800 direct

    LOREN STEFAN - Director

    2022-08-01 18:01:20 -0400 2022-06-24 A 7,800 a 7,800 direct

    DRISCOLL FREDERICK W - Director

    2022-08-01 18:00:54 -0400 2022-06-24 A 7,800 a 7,800 direct

    CHANAN-KHAN ASHER - Director

    2022-08-01 18:00:52 -0400 2022-06-24 A 7,800 a 7,800 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    CELLECTAR BIOSCIENCES INC CLRB 2022-08-18 22:15:04 UTC -7.6264 9.9464 100000
    CELLECTAR BIOSCIENCES INC CLRB 2022-08-18 21:45:04 UTC -7.673 9.993 100000
    CELLECTAR BIOSCIENCES INC CLRB 2022-08-18 21:15:04 UTC -7.673 9.993 100000
    CELLECTAR BIOSCIENCES INC CLRB 2022-08-18 20:45:04 UTC -7.3654 9.6854 100000
    CELLECTAR BIOSCIENCES INC CLRB 2022-08-18 20:15:04 UTC -7.3654 9.6854 100000
    CELLECTAR BIOSCIENCES INC CLRB 2022-08-18 19:45:04 UTC -7.3654 9.6854 100000
    CELLECTAR BIOSCIENCES INC CLRB 2022-08-18 19:15:04 UTC -7.3654 9.6854 100000
    CELLECTAR BIOSCIENCES INC CLRB 2022-08-18 18:45:04 UTC -7.3654 9.6854 100000
    CELLECTAR BIOSCIENCES INC CLRB 2022-08-18 18:15:05 UTC -7.3654 9.6854 100000
    CELLECTAR BIOSCIENCES INC CLRB 2022-08-18 17:45:04 UTC -7.3654 9.6854 100000
    CELLECTAR BIOSCIENCES INC CLRB 2022-08-18 17:15:04 UTC -7.3654 9.6854 100000
    CELLECTAR BIOSCIENCES INC CLRB 2022-08-18 16:45:04 UTC -7.3654 9.6854 100000
    CELLECTAR BIOSCIENCES INC CLRB 2022-08-18 16:15:03 UTC -7.3654 9.6854 100000
    CELLECTAR BIOSCIENCES INC CLRB 2022-08-18 15:45:04 UTC -7.3654 9.6854 100000
    CELLECTAR BIOSCIENCES INC CLRB 2022-08-18 15:15:05 UTC -7.3654 9.6854 100000
    CELLECTAR BIOSCIENCES INC CLRB 2022-08-18 14:45:04 UTC -7.3654 9.6854 100000
    CELLECTAR BIOSCIENCES INC CLRB 2022-08-18 14:15:05 UTC -7.3654 9.6854 100000
    CELLECTAR BIOSCIENCES INC CLRB 2022-08-18 13:45:04 UTC -7.3654 9.6854 100000
    CELLECTAR BIOSCIENCES INC CLRB 2022-08-18 13:15:04 UTC -7.3654 9.6854 100000
    CELLECTAR BIOSCIENCES INC CLRB 2022-08-18 12:45:05 UTC -7.3654 9.6854 100000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments